ArticleAmerican journal of translational research2023
Clinical characteristics and survival analysis of class I pulmonary arterial hypertension.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze the clinical data and prognosis of patients with World Health Organization (WHO) functional class I pulmonary arterial hypertension (PAH).
methodsThis research retrospectively analyzed the clinical data (baseline, laboratory as well as echocardiography and right heart catheterization data) of 63 class I PAH patients diagnosed and treated in the Department of Cardiology, First Affiliated Hospital of Zhengzhou University, between January 2021 and June 2022. The mean follow-up time was 10.7±6.5 months. The treatment and prognosis of the patients were analyzed.
resultsAmong the class I PAH patients, the average age at diagnosis was 39.7±12.7 years, with females accounting for 92.1%; 44.4% of patients were at grade III or IV; 55.6% were at medium-high risk. In the subgroup analysis, there were more cases with grade III/IV cardiac function (
conclusionsIn the era of targeted therapy, class I PAH patients in China have a high early survival rate, a high proportion of combined therapy and strong multidisciplinary attention.
Indexed as
Identifiers
36915738PMC10006787W4324130320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.